- HK$55.42bn
- HK$129.72bn
- CNY584.51bn
- 62
- 95
- 31
- 71
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 6.37 | ||
| PEG Ratio (f) | 1.7 | ||
| EPS Growth (f) | 3.89% | ||
| Dividend Yield (f) | 4.72% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.66 | ||
| Price to Tang. Book | 0.75 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.09 | ||
| EV to EBITDA | 5.71 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 10.6% | ||
| Return on Equity | 9.19% | ||
| Operating Margin | 2.58% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | 456,414.61 | 521,051.23 | 552,147.55 | 596,569.56 | 584,507.93 | 607,191.77 | 635,319.41 | 6.57% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +9.38 | +12.29 | +4.47 | +1.86 | -10.27 | +2.79 | +6.3 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Sinopharm Group Co Ltd is a China-based company principally engaged in the wholesale and retail of pharmaceutical and healthcare products and medical devices. The Company operates its business through four segments. The Pharmaceutical Distribution segment provides distribution, logistics and other value-added services to domestic and foreign pharmaceutical and health product manufacturers and other suppliers. The Device Distribution segment distributes medical devices to customers. The Pharmaceutical Retail Business segment owns a network of retail pharmacies that are directly operated or franchised. The Other Business segment is engaged in the manufacture and sale of pharmaceuticals, chemical reagents and laboratory supplies.
Directors
- Qingming Yu CHM (57)
- Yong Liu PRE (52)
- Qiyu Chen NVC
- Xiaojuan Li CFO (45)
- Maisong Cai VPR (51)
- Zhanyu Chen VPR (50)
- Xiuchang Jiang VPR (57)
- Yang Li VPR (42)
- Wanyong Lian VPR (51)
- Shuangjun Xu VPR (53)
- Xudong Zhou VPR (51)
- Yijian Wu SEC (51)
- Jindong Deng NED (56)
- Rongli Feng NED (46)
- Xiaohui Guan NED (50)
- Jianwei Hu NED (47)
- Dongjiu Li NED (56)
- Ping Ma NED (65)
- Deyong Wen NED (50)
- Fangruo Chen NID (56)
- Peiyu Li NID (58)
- Tak Lung Wu NID (56)
- Weifeng Yu NID (50)
- Fumin Zhuo NID (70)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 8th, 2003
- Public Since
- September 23rd, 2009
- No. of Employees
- 113,635
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Stock Exchange of Hong Kong Limited- Shares in Issue
- 3,120,656,191
- Address
- Sinopharm Group Building, No. 385, East, SHANGHAI, 200023
- Web
- https://www.sinopharmgroup.com.cn/
- Phone
- +86 2123052666
- Auditors
- PricewaterhouseCoopers
Upcoming Events for 1099
Dividend For 1099.HK - 0.6800 CNY
Sinopharm Group Co Ltd Annual Shareholders Meeting
Half Year 2025 Sinopharm Group Co Ltd Earnings Release
Similar to 1099
3D Medicines
Stock Exchange of Hong Kong Limited
3SBio
Stock Exchange of Hong Kong Limited
AIM Vaccine Co
Stock Exchange of Hong Kong Limited
Ascletis Pharma
Stock Exchange of Hong Kong Limited
Asymchem Laboratories Tianjin Co
Stock Exchange of Hong Kong Limited
FAQ
What is the Sinopharm Co share price?
As of Today at 23:16 UTC, shares in Sinopharm Co are trading at HK$17.76. This share price information is delayed by 15 minutes.
How has the Sinopharm Co share price performed this year?
Shares in Sinopharm Co last closed at HK$17.76 and the price had moved by -10.48% over the past 365 days. In terms of relative price strength the Sinopharm Co share price has underperformed the FTSE Developed Asia Pacific Index by -7.94% over the past year.
What are the analyst and broker recommendations for Sinopharm Co?
The overall consensus recommendation for Sinopharm Co is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Sinopharm Co dividend yield?
The Sinopharm Co dividend yield is 4.07% based on the trailing twelve month period.
Does Sinopharm Co pay a dividend?
Last year, Sinopharm Co paid a total dividend of CNY0.68, and it currently has a trailing dividend yield of 4.07%.Looking ahead, shares in Sinopharm Co are due to go ex-dividend on 2025-06-16 and the next dividend pay date is 2025-08-12.
When does Sinopharm Co next pay dividends?
Sinopharm Co are due to go ex-dividend on 2025-06-16 and the next dividend pay date is 2025-08-12. The historic dividend yield on Sinopharm Co shares is currently 4.07%.
How do I buy Sinopharm Co shares?
To buy shares in Sinopharm Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Sinopharm Co?
As of the previous close price of HK$17.76, shares in Sinopharm Co had a market capitalisation of HK$55.42bn.
Where are Sinopharm Co shares listed?
Here are the trading details for Sinopharm Co:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 1099
What kind of share is Sinopharm Co?
Based on an overall assessment of its quality, value and momentum Sinopharm Co is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Sinopharm Co share price forecast for 2025?
The analyst consensus target price for shares in Sinopharm Co is HK$21.97. That is 23.7% above the last closing price of HK$17.76.
Analysts covering Sinopharm Co currently have a consensus Earnings Per Share (EPS) forecast of CNY2.57 for the next financial year.
Find out moreWhat is the trend in the Sinopharm Co share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sinopharm Co. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -3.01%.
As of the last closing price of HK$17.76, shares in Sinopharm Co were trading -9.63% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Sinopharm Co PE Ratio?
The Sinopharm Co PE ratio based on its reported earnings over the past 12 months is 6.37. The shares last closed at HK$17.76.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Sinopharm Co?
Sinopharm Co's management team is headed by:
- Qingming Yu - CHM
- Yong Liu - PRE
- Qiyu Chen - NVC
- Xiaojuan Li - CFO
- Maisong Cai - VPR
- Zhanyu Chen - VPR
- Xiuchang Jiang - VPR
- Yang Li - VPR
- Wanyong Lian - VPR
- Shuangjun Xu - VPR
- Xudong Zhou - VPR
- Yijian Wu - SEC
- Jindong Deng - NED
- Rongli Feng - NED
- Xiaohui Guan - NED
- Jianwei Hu - NED
- Dongjiu Li - NED
- Ping Ma - NED
- Deyong Wen - NED
- Fangruo Chen - NID
- Peiyu Li - NID
- Tak Lung Wu - NID
- Weifeng Yu - NID
- Fumin Zhuo - NID